<DOC>
	<DOCNO>NCT02527941</DOCNO>
	<brief_summary>A non-randomized , interventional , longitudinal clinical study quantify impact bacterial vaginosis treatment HIV susceptibility genital immunology Kenyan woman .</brief_summary>
	<brief_title>Effect Bacterial Vaginosis HIV Susceptibility Female Genital Immunology</brief_title>
	<detailed_description>Bacterial Vaginosis ( BV ) , define alteration normal vaginal bacteria ( `` microbiome '' ) , characterize reduction hydrogen peroxide-producing gram-positive lactobacillus overgrowth gram-negative anaerobic bacteria . BV prevalent SSA usually recur soon treatment . BV associate vaginal inflammation , increase HIV acquisition risk among uninfected woman , increase HIV transmission male sexual partner co-infected woman . Therefore , BV may responsible 17 % HIV transmission event SSA . There several hypothesis mechanism BV may increase risk HIV acquisition . These include disruption mucosal barrier , alteration protective innate immunity , increase number and/or susceptibility HIV target cell genital mucosa . Longitudinal study address mechanisms vaginal microbiota alters host mucosal immunology HIV risk help u good understand impact BV 's treatment mucosal immunology HIV susceptibility . The goal non-randomized , interventional , longitudinal clinical study use novel ex vivo HIV infectivity assay develop Kaul lab quantify effect BV treatment HIV susceptibility genital immunology HIV-uninfected woman Nairobi , Kenya . Fifty HIV , STI-uninfected woman bacterial vaginosis Nugent scoring provide one week metronidazole 400mg po three time daily ( per Kenyan National Guidelines ) . Cytobrush vaginal SoftCup sampling perform baseline 4 week treatment initiation , stage menstrual cycle . The primary endpoint pseudovirus entry cervix-derived CD4+ T cell . Secondary endpoint include pre-defined cervico-vaginal inflammation score ; genital CD4+ T cell immune characteristic ; genital microbiome ; genital proteome .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1 . Participants 18 year age , pregnant willing give inform consent , answer short questionnaire economic status , sexual risk behavior . 2 . Willing comply requirement protocol 3 . HIV classical STI ( see ) negative 4. test positive BV , define Nugent score 710 5. willing take oral metronidazole twice day 7 day 6. willing abstain alcohol 48 hour metronidazole treatment 1 . HIV infect 2 . Deemed physician unlikely complete study protocol . 3 . Pregnant . 4 . Irregular menstrual cycle , actively menstruate time genital sampling . 5 . Tested positive classical STIs genital ulcer 6 . Prior hysterectomy 7 . Contraindication , allergy intolerance use metronidazole</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Genital immunology</keyword>
	<keyword>HIV susceptibility</keyword>
	<keyword>Microbiome</keyword>
	<keyword>Bacterial vaginosis</keyword>
	<keyword>Virus entry assay</keyword>
</DOC>